Medical Devices DECODED
Previous edition: 09 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Biotechs must prioritise ethics to deter GenAI “bad actors”
At the London Biotechnology Show, Microsoft’s senior director of life sciences discussed the ethical use of GenAI.
AI developers in the biotechnology field need to watch out for potential “bad actors”, who could use the technology for malicious purposes, says Thomas Balkizas, the senior director of life sciences at Microsoft.
At the London Biotechnology Show, taking place from 8 to 9 May, Balkizas led a talk covering the advent of generative AI (GenAI) in the biotech sector. He reported Microsoft data that projected $150bn in savings for healthcare providers by 2026 if they chose to use AI to prevent errors in medication dosing. He said the technology could be used for different purposes such as increasing diversity in clinical trial recruitment, improving treatment options for neonatal care and more.
At the same time, however, Balkizas highlighted the importance of considering ethical questions in ongoing discussions of AI applications.
GenAI is AI that can produce text, images, videos, or other types of data using generative models. The technology can learn and adapt to patterns in the data to generate new data. Since the launch of large language models such as OpenAI’s ChatGPT in November 2022 and Google DeepMind’s Gemini in March 2023, GenAI has become a mainstream topic of discussion.
Balkizas warned that in a biotechnology context, if in the wrong hands, GenAI technology could be used to develop things such as biological weapons. Before a wider framework for AI regulations and ethics is developed, Balkizas stated that individual companies would need to prioritise setting principles to maintain ethical practices.
Microsoft‘s AI principles include a commitment to designing AI systems that perform safely, even in the worst-case scenario, and developing systems that protect data from misuse and enable privacy rights. Furthermore, the company has prioritised the design of AI systems that do not “reinforce undesirable stereotypes and biases,” says Balkizas. However, he adds that the next step lies in developing more public policies for the correct use of GenAI in biotech.
In February, Microsoft announced a partnership with 1910 Genetics to use a multimodal AI platform for drug discovery. The tech giant also announced the expansion of its collaboration with NVIDIA in March, combining Microsoft’s Azure platform with NVIDIA DGX Cloud and NVIDIA Clara to build new AI medical imaging models and faster routes to drug discovery.
Latest news
15th Annual Outsourcing in Clinical Trials East Coast 2024
The upcoming Outsourcing in Clinical Trials Europe 2024 conference will explore advancements in the clinical trial industry.
FDA issues warning on Getinge device amid quality concerns
Following a series of voluntary recalls, the FDA has urged healthcare providers to avoid Getinge’s intra-aortic balloon pumps over safety concerns.
4C Medical's AltaValve gains dual breakthrough designations from FDA
The device has received the designation for treating mitral regurgitation and mitral annular calcification.
UK report warns that economic instability is threatening life sciences sector
The report published by the Medicines Discovery Catapult warns that a mix of economic uncertainty and lack of facility access is pushing investors away from Britain’s healthcare SMEs.
Biosense introduces CARTO 3 System Version 8
The latest version features new modules, including the CARTO ELEVATE Module and CARTOSOUND FAM Module.
Qiagen and FBI partner on DNA quant digital PCR assays
The collaboration aims to develop a first-of-its-kind digital PCR assay capable of detecting and quantifying minimal amounts of DNA with high accuracy.
Vivalink introduces new solution for MCT and Holter monitoring
The new technology combines RPM technologies with advanced arrhythmia detection algorithms.
iHealth's COVID-19/Flu rapid test secures FDA EUA
Intended for over-the-counter use, the 3-in-1 test is intended for detecting Covid-19 and influenzas A and B.
Leica Microsystems adds Viventis Microscopy to portfolio
The addition of Viventis adds light sheet technology to Leica’s line of research microscopes.
In our previous edition
Medical Devices Decoded
Samsung to acquire foetal ultrasound AI software company Sonio
08 May 2024
Medical Devices Decoded
Medtronic's renal denervation system receives approval in China
07 May 2024
Medical Devices Decoded
Angle signs AstraZeneca deal to develop prostate cancer assay
06 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Medical Devices
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer